Company Filing History:
Years Active: 1994-1997
Title: Michael A Skinner: Innovator in Vaccine Development
Introduction
Michael A Skinner is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of vaccine development, holding a total of 3 patents. His work focuses on attenuated viruses, which are crucial for creating effective vaccines.
Latest Patents
Among his latest patents, Skinner has developed an attenuated enterovirus or rhinovirus suitable for use as a vaccine. This invention features a reversed base pairing in the 5' non-coding region of the genome of poliovirus type 3 Leon strain. Specifically, a suitable attenuated poliovirus has the bases G and C at positions 469 and 534 for type 1 or type 2 poliovirus, or at positions 472 and 537 for type 3 poliovirus. Another patent involves an attenuated poliovirus that has an attenuating mutation at positions corresponding to 471 or 484 of the genome of poliovirus type 3 Leon strain.
Career Highlights
Michael A Skinner is associated with the British Technology Group Limited, where he continues to innovate in the field of virology and vaccine research. His work has been instrumental in advancing the understanding and application of attenuated viruses in vaccine development.
Collaborations
Skinner has collaborated with notable colleagues in his field, including Jeffrey William Almond and Philip D Minor. Their combined expertise has contributed to the success of various projects and patents.
Conclusion
Michael A Skinner's contributions to vaccine development through his innovative patents highlight his role as a key figure in the field. His work continues to pave the way for advancements in public health and disease prevention.